Radiofrequency ablation of hepatocellular carcinoma: Current status, challenges, and prospects

Abstract

Local ablation technologies, such as radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation, have become a standard treatment option for hepatocellular carcinoma (HCC) less than 5 cm in size, particularly in individuals who are not candidates for hepatectomy. Except for equivalent prognosis and efficiency, RFA has various advantages over surgical excision, including a lower rate of complications, a cheaper cost, more normal tissue preservation, and a shorter hospital stay. However, the rate of tumor recurrence and/or distant metastasis after RFA therapy is still high. RFA has been widely employed in multiple cancers, large cancer, and lesion identified at “high-risk” sites in recent years, with the advancement of ablation types and operating techniques, particularly the combined use of many technologies. The real value of RFA technology has been more fully reflected. We will examine the status, progress, and problems of RFA in the treatment of HCC in this review.

Keywords

• Radiofrequency ablation (RFA)
• Hepatocellular carcinoma (HCC)
• Combined therapy
• Immunotherapy
• Transarterial chemoembolization (TACE)
• Tyrosine kinase inhibitors (TKIs)